神經內分泌腫瘤（NETs）：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2035 年，西班牙淨市場規模將從約 4.5 億美元成長到 8.5 億美元。
• 市場成長受以下因素支撐：
• 標靶治療和胜肽受體放射性核素治療（PRRT）的廣泛應用
• 改善診斷技術和長期疾病監測
• 市場規模的擴大是由治療週期延長和個人化癌症治療方法所推動的。
• 未來的成長取決於新型標靶治療和放射性配體療法的廣泛應用。

神經內分泌腫瘤（NETs）概述

神經內分泌腫瘤（NETs）是一組起源於瀰漫性神經內分泌系統分泌細胞的異質性腫瘤，最常見於胃腸道、胰臟和肺，其特徵是荷爾蒙分泌活性多樣以及生長抑制素受體過度表現。根據Ki-67生長指數，分化良好的NETs分為G1至G3級，而分化不良的神經內分泌癌則是另一組侵襲性較強的疾病。功能性NETs可引起荷爾蒙症候群，例如類癌症候群、胰島素瘤和胃泌素瘤，而非功能性NETs則常為偶然發現或表現為腫瘤壓迫症狀。診斷方法包括特異性荷爾蒙水平檢測、DOTATATE PET-CT（在病灶檢測和分期方面表現出色）以及新型的基於mRNA的血液檢測，例如NETest。由於嗜鉻粒蛋白A特異性低、質子幫浦阻斷劑使用時常出現假陽性結果以及效用有限，其作為監測工具的重要性正在降低。手術切除仍是根治性治療的基礎。生長抑制素類似物Octreotide和Lanreotide具有抑制腫瘤生長和抑制腫瘤分泌的作用。基於NETTER-2試驗的數據，鎦-177多肽現已確立為進行性、重度生長抑素受體陽性2級和3級生長抑制素（GEP-NETs）的一線標準治療方案，這標誌著與傳統晚期治療方案的根本性轉變。Everolimus和Sunitinib異性作用於胰臟神經內分泌腫瘤（NETs），而四曲司他乙酯可抑制難治性類癌症候群相關的腹瀉。預後取決於惡性程度和病變範圍，但多學科管理和以患者為中心的症狀管理對於最佳化治療效果至關重要。

主要亮點

• 根據預測，德國神經內分泌腫瘤新發病例數將從 2025 年的約 2,102 例增加到 2035 年的 2,272 例。
• 診斷影像技術的進步和基於生物標記的診斷方法的廣泛應用，提高了疾病的檢出率。
• 神經內分泌腫瘤是一組異質性腫瘤，有不同的臨床表現和預後。
• 治療選擇不斷增加，包括生長抑制素類似物、標靶治療和胜肽受體放射性核素治療（PRRT）。
• 公眾意識的提高和早期診斷的普及改善了患者的治療效果。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Orano Med LLC
• ITM Solucin GmbH
• Clarity Pharmaceuticals Ltd.
• Crinetics Pharmaceuticals Inc.
• TaiRx, Inc.
• Advanced Accelerator Applications
• Novartis Pharmaceuticals
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Boehringer Ingelheim
• Perspective Therapeutics
• Harbour BioMed（Guangzhou）Co. Ltd.
• Exelixis
• Hutchmed
• Sichuan Baili Pharmaceutical Co., Ltd.
• Chimeric Therapeutics
• BioXcel Therapeutics Inc.
• Teclison Ltd.
• Circle Pharma
• SAPU NANO（US）LLC
• EpicentRx, Inc.
• Novelty Nobility, Inc.
• Arbele Pty Ltd.
• Hoffmann-La Roche

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期管道

第6章：未滿足的需求與TPP分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Neuroendocrine Tumors (NETs) Market Outlook

Thelansis's "Neuroendocrine Tumors (NETs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroendocrine Tumors treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuroendocrine Tumors (NETs) Overview

Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms arising from secretory cells of the diffuse neuroendocrine system, occurring most commonly in the gastroenteropancreatic tract and lungs, characterised by variable hormonal secretory activity and somatostatin receptor overexpression. Well-differentiated NETs are graded G1 through G3 by Ki-67 proliferative index, while poorly differentiated neuroendocrine carcinomas represent a distinct aggressive entity. Functioning tumors produce hormonal syndromes including carcinoid syndrome, insulinoma, and gastrinoma, while non-functioning tumors present incidentally or with mass-effect symptoms. Diagnosis integrates specific hormonal assays, DOTATATE PET-CT for superior lesion detection and staging, and emerging mRNA-based blood assays including NETest; chromogranin A is increasingly de-emphasised given poor specificity, frequent false positivity with proton pump inhibitor use, and limited monitoring utility. Surgical resection remains the cornerstone of curative intent. Somatostatin analogues octreotide and lanreotide provide antiproliferative and antisecretory benefits. Lutetium-177 DOTATATE, supported by NETTER-2 trial data, is now established as first-line standard of care for advanced, high-burden somatostatin receptor-positive Grade 2 and Grade 3 GEP-NETs, representing a fundamental repositioning from later-line therapy. Everolimus and sunitinib address pancreatic NETs specifically, while telotristat ethyl controls refractory carcinoid syndrome diarrhoea. Prognosis varies with grade and disease extent; multidisciplinary management and patient-centred symptom control are integral to optimising outcomes.

Key Highlights

• In Germany, incident neuroendocrine tumor cases are projected to increase from approximately 2,102 in 2025 to 2,272 by 2035.
• Improved imaging and biomarker-based diagnostics are contributing to increased disease detection.
• NETs represent a heterogeneous group of tumors with varying clinical behavior and prognosis.
• Somatostatin analogs, targeted therapies, and peptide receptor radionuclide therapy (PRRT) continue to expand treatment options.
• Rising awareness and earlier diagnosis are supporting improved patient outcomes.

Market Overview

• The Spain NET market is projected to grow from approximately $450 MN to $850 MN by 2035.
• Market growth is supported by:
• Increasing adoption of targeted therapies and PRRT
• Improved diagnosis and long-term disease monitoring
• Market value growth is driven by extended treatment duration and personalized oncology approaches.
• Future growth will depend on novel targeted therapies and expanded use of radioligand treatments.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Orano Med LLC
• ITM Solucin GmbH
• Clarity Pharmaceuticals Ltd.
• Crinetics Pharmaceuticals Inc.
• TaiRx, Inc.
• Advanced Accelerator Applications
• Novartis Pharmaceuticals
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Boehringer Ingelheim
• Perspective Therapeutics
• Harbour BioMed (Guangzhou) Co. Ltd.
• Exelixis
• Hutchmed
• Sichuan Baili Pharmaceutical Co., Ltd.
• Chimeric Therapeutics
• BioXcel Therapeutics Inc.
• Teclison Ltd.
• Circle Pharma
• SAPU NANO (US) LLC
• EpicentRx, Inc.
• Novelty Nobility, Inc.
• Arbele Pty Ltd.
• Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)